It is only three years ago that Merck & Co. Inc. got its first approval for Keytruda (pembrolizumab) in melanoma and data presented at the European Society for Medical Oncology congress in Madrid has highlighted how dominant the PD-1 inhibitor has become in such a short space of time.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?